Leerink analyst Daniel Clark raised the firm’s price target on Idexx Laboratories (IDXX) to $600 from $580 and keeps an Outperform rating on the shares. The firm continues to like Idexx’s setup over the next few years and raises its 12-month price target following channel checks and its semiannual veterinarian survey.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX: